英诺皮肤活化剂治疗光化性角化病的作用。
The role of ingenol mebutate in the treatment of actinic keratoses.
机构信息
Dermatological Sciences, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK.
出版信息
Dermatol Ther (Heidelb). 2012 Dec;2(1):8. doi: 10.1007/s13555-012-0008-4. Epub 2012 Jun 7.
Abstract
Actinic keratoses (AK) are the most common premalignant pathology seen in dermatological practice and represent a burgeoning burden upon health services. Increasingly recognized is the damage to surrounding, perilesional skin, forming the premise for field-directed therapy. Ingenol mebutate gel is a novel agent for field-directed treatment of AK, requiring only 2 or 3 days of application. Following an overview of existing treatment modalities, the authors review recent trials and safety data pertaining to the use of ingenol mebutate gel and discuss its role in the treatment of AK.
摘要
光化性角化病（AK）是皮肤科最常见的癌前病变，对卫生服务系统造成了越来越大的负担。人们越来越认识到周围病变皮肤的损伤，这为定向治疗提供了前提。 Ingenol 咪喹莫特凝胶是一种用于 AK 定向治疗的新型药物，仅需应用 2 至 3 天。在概述了现有的治疗方法后，作者回顾了 Ingenol 咪喹莫特凝胶的近期临床试验和安全性数据，并讨论了其在 AK 治疗中的作用。
相似文献
1
The role of ingenol mebutate in the treatment of actinic keratoses.英诺皮肤活化剂治疗光化性角化病的作用。
Dermatol Ther (Heidelb). 2012 Dec;2(1):8. doi: 10.1007/s13555-012-0008-4. Epub 2012 Jun 7.
2
3
Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.外用 ingenol 甲丁酯：一种治疗多发性光化性角化病和场癌化的新方法。
Anticancer Agents Med Chem. 2017;17(10):1304-1311. doi: 10.2174/1871520617666170213130523.
4
Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.探索鬼臼毒素酯预防非黑色素瘤皮肤癌的用途。
Dan Med J. 2017 Nov;64(11).
5
Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.0.015%和 0.05%水扬酸吉妥珠单抗凝胶：光化性角化病。
Drugs. 2012 Dec 24;72(18):2397-405. doi: 10.2165/11470090-000000000-00000.
6
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.0.025%和0.05%鬼臼毒素丁酯凝胶治疗光化性角化病的随机、双盲、双模拟、赋形剂对照研究
J Am Acad Dermatol. 2009 Jun;60(6):934-43. doi: 10.1016/j.jaad.2009.01.008.
7
Ingenol mebutate gel for actinic keratosis.咪喹莫特乳膏治疗光化性角化病。
N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.
8
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.长期随访研究表没食子儿茶素没食子酸酯凝胶治疗光化性角化病。
JAMA Dermatol. 2013 Jun;149(6):666-70. doi: 10.1001/jamadermatol.2013.2766.
9
Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.分析喜树碱治疗光化性角化病后与细胞凋亡相关的分子：红细胞分化调节因子 1、bcl-2 和 p53。
Exp Dermatol. 2017 Nov;26(11):1012-1017. doi: 10.1111/exd.13349. Epub 2017 Jul 3.
10
Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.咪喹莫特治疗光化性角化病的安全性和耐受性。
Expert Opin Drug Saf. 2015;14(12):1969-78. doi: 10.1517/14740338.2015.1108962. Epub 2015 Nov 2.
引用本文的文献
1
Enhancing titers of therapeutic lentiviral vectors using PKC agonists.使用蛋白激酶C激动剂提高治疗性慢病毒载体的滴度。
Mol Ther Methods Clin Dev. 2025 May 7;33(2):101484. doi: 10.1016/j.omtm.2025.101484. eCollection 2025 Jun 12.
2
Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.咪喹莫特在光化性角化病治疗中的临床应用：来自临床实践的观点。
Ther Clin Risk Manag. 2018 Oct 4;14:1879-1885. doi: 10.2147/TCRM.S145779. eCollection 2018.
3
Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers.ingenol Disoxate：一种新型的ingenol 4-异恶唑羧酸酯，具有改善的性质，用于治疗光化性角化病和其他非黑色素瘤皮肤癌。
Dermatol Ther (Heidelb). 2016 Dec;6(4):599-626. doi: 10.1007/s13555-016-0137-2. Epub 2016 Aug 8.
4
Laser-assisted drug delivery in dermatology: from animal models to clinical practice.皮肤科的激光辅助药物递送：从动物模型到临床实践。
Lasers Med Sci. 2016 Feb;31(2):373-81. doi: 10.1007/s10103-015-1853-z. Epub 2015 Dec 22.
5
Novel medical strategies combating nonmelanoma skin cancer.对抗非黑色素瘤皮肤癌的新型医学策略。
Indian J Dermatol. 2014 Nov;59(6):531-46. doi: 10.4103/0019-5154.143503.
6
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.来自麻风树的新型大戟醇衍生物在HIV复制中的双重作用：抑制从头感染和激活病毒长末端重复序列
PLoS One. 2014 May 14;9(5):e97257. doi: 10.1371/journal.pone.0097257. eCollection 2014.
7
Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients.光动力疗法在器官移植受者光化性角化病治疗中的应用。
Biomed Res Int. 2013;2013:349526. doi: 10.1155/2013/349526. Epub 2012 Dec 24.
本文引用的文献
1
Ingenol mebutate gel for actinic keratosis.咪喹莫特乳膏治疗光化性角化病。
N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.
2
Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.成纤维细胞生长因子受体 2 单克隆抗体（faricimab）治疗湿性年龄相关性黄斑变性的疗效和安全性：两年的疗效和安全性数据
J Invest Dermatol. 2012 Apr;132(4):1263-71. doi: 10.1038/jid.2011.418. Epub 2011 Dec 22.
3
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response.英诺皮肤活化剂凝胶治疗光化性角化病的双重作用机制：快速病变坏死和随后的病变特异性免疫应答。
J Am Acad Dermatol. 2012 Mar;66(3):486-93. doi: 10.1016/j.jaad.2010.12.038. Epub 2011 Nov 4.
4
The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.飞扬草的汁液能有效对抗人类非黑色素瘤皮肤癌。
Br J Dermatol. 2011 Mar;164(3):633-6. doi: 10.1111/j.1365-2133.2010.10184.x. Epub 2011 Jan 27.
5
Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.光化性角化病的治疗是非黑素瘤皮肤癌预防策略的关键组成部分。
J Clin Aesthet Dermatol. 2010 Jun;3(6):39-44.
6
Non-melanoma skin cancer.非黑素瘤皮肤癌。
Lancet. 2010 Feb 20;375(9715):673-85. doi: 10.1016/S0140-6736(09)61196-X.
7
PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.PEP005（鬼臼毒素）凝胶，一种治疗光化性角化病的新型药物：一项随机、双盲、赋形剂对照、多中心IIa期研究的结果。
Australas J Dermatol. 2009 Feb;50(1):16-22. doi: 10.1111/j.1440-0960.2008.00497.x.
8
Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues.光化性角化病与鳞状细胞癌之间的交叉点以及新的药理学问题。
Eur J Dermatol. 2008 Jan-Feb;18(1):6-10. doi: 10.1684/ejd.2008.0303. Epub 2007 Dec 18.
9
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification.光化性角化病是一种早期原位鳞状细胞癌：重新分类的提议。
Br J Dermatol. 2007 May;156 Suppl 3:8-12. doi: 10.1111/j.1365-2133.2007.07860.x.
10
Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions.欧洲非黑素瘤皮肤癌（NMSC）的流行病学：有效的公共卫生监测和干预需要准确且可比的数据。
Br J Dermatol. 2007 May;156 Suppl 3:1-7. doi: 10.1111/j.1365-2133.2007.07861.x.
Zotero 插件